Vol. 18/ No. 21 | OncologyLive

Triplet Therapy With Selinexor Tested in Myeloma

December 04, 2017

Selinexor, a novel drug that targets a tumor-suppressor “cargo” protein mechanism, is being investigated in patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior treatment regimens.

New Diagnostic Assays in the Works to Test for TRK Fusions

November 16, 2017

Oncogenic fusions involving TRK proteins have been implicated in various cancer types, prompting clinical development of therapies targeting the aberrations across histologies rather than their body site of origin.

Novel Hormone Strategies Gain Ground in Breast Cancer

November 16, 2017

Although hormone-targeting therapies have been a long-established strategy for the treatment of estrogen receptor (ER)-positive breast cancer, more than 20% of patients with early-stage disease relapse and those who progress to a metastatic stage eventually die from their illness.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 07, 2017

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

AKT1 E17K Mutation Targetable in Various Tumors Through AKT Inhibition

November 03, 2017

A multihistology basket study proved the targetability of the AKT1 E17K mutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K mutation with AZD5363, an oral pan-AKT inhibitor,

International Panel Describes Evolving Challenges in HCC

November 02, 2017

Although new therapies are being rapidly introduced in the hepatocellular carcinoma field after years of clinical trial disappointments, clinicians face many challenges when treating patients with this malignancy, including delays in diagnosis and comorbidities.